Purpose Despite significant advances in antiemetic management, almost 50% of cancer patients still experience nausea and vomiting during treatment. The goal of antiemetic therapy is complete prevention of treatmentinduced nausea and/or vomiting (TINV); however, realisation of this goal remains elusive, thus supplementary strategies identifying patients at high risk must be employed in the interim. Consequently, we examined TINV incidence and its risk factors, including patient, clinical and pretreatment quality of life (QOL)/psychological factors. Methods Two hundred newly diagnosed cancer patients beginning combined treatment participated in this prospective, longitudinal, observational study. QOL (including TINV), psychological adjustment, and patient/clinical characteristics were examined at pretreatment, on-treatment (8 weeks±1 week) and post-treatment. Results Overall, 62% of patients experienced TINV, with TIN incidence (60%) doubling that of TIV (27%). Eight independent risk factors predicted 73% of TIN incidence: high premorbid/anticipatory NV, moderately/highly emetogenic chemotherapy (M/HEC), longer treatment (>3 months), female gender, surgery prior to adjuvant chemotherapy ± radiotherapy, private health insurance and low emotional functioning (pretreatment). Six independent risk factors predicted 77% of TIV incidence: premorbid/ anticipatory vomiting, M/HEC, female gender, cancer resection and low role functioning (pretreatment). Conclusions TINV still represents a very major concern for patients. Several pretreatment risk factors for the development of TIN and TIV, respectively, were identified. Patients about to undergo cancer treatment, particularly combined treatment involving emetogenic chemotherapy and surgery, should be screened for these factors with a view to modifying standard pretreatment/maintenance antiemetic therapy. Furthermore, and consistent with recent research, it is recommended that more comprehensive interventions combining antiemetics with other effective pharmacological (e.g. anxiolytics) and non-pharmacological approaches (e.g. acupuncture, relaxation techniques) be considered by clinicians in attempts to improve control of TIN and TIV (and overall QOL) for their patients. In this way, optimal holistic care will be ensured for cancer patients by clinicians providing conventional oncology treatment.
Introduction
In the 1980s cancer patients ranked nausea and vomiting (NV) as the most distressing side effects of chemotherapy [1] , resulting in up to 33% refusing, delaying or abandoning potentially curative treatment [2] . Despite significant advances in antiemetic therapy with the introduction of serotonin (5-HT 3 ) and neurokinin (NK-1) receptor antagonists and prescriptive guidelines for their use, patients remain fearful [3, 4] with almost 50% still experiencing NV during treatment (Table 1) [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] .
Cancer patients have genuine cause for concern. Poorly controlled treatment-induced nausea and/or vomiting (TINV) attributed to chemotherapy, radiotherapy and/or surgery has a range of negative consequences, including physical complications (e.g. anorexia, fatigue) [2] ; impaired daily functioning and overall quality of life (QOL) for patients and their caregivers (e.g. disrupted social life, lost work days) [8, 12, 13, 16, [18] [19] [20] ; increased medical costs due to greater use of health care resources (e.g. unscheduled appointments, emergency/hospital admissions, rescue medications) [14, 16] ; and psychosocial distress (e.g. anxiety, phobias including anticipatory NV) [18, 20] . Furthermore, uncontrolled TINV may lead to treatment dose reductions/ delays, non-compliance or cessation, thereby decreasing patients' chances of prolonged survival or cure [2] .
Current evidence-based antiemetic guidelines (e.g. Multinational Association of Supportive Care in Cancer [21] , American Society of Clinical Oncology [22] , National Comprehensive Cancer Network [23] ) maintain that the goal of antiemetic therapy is complete NV prevention. The inability, thus far, to achieve a desirable level of control for all patients is multifactorial. Reasons include the use of increasingly emetogenic chemotherapy regimens [24, 25] ; incomplete understanding of the mechanisms underlying TINV; underestimation of TINV incidence, especially delayed emesis [26] ; lack of compliance with antiemetic guidelines [15, 25] ; infrequent/inadequate assessment of TINV and its risk factors in routine clinical practice; antiemetic coverage being biased toward vomiting at the expense of nausea [4, 25] ; and previous studies examining TINV within the constraints of clinical trials [14, 25] .
Assessing risk factors at pretreatment could help identify patients at high risk for TINV and lead to significantly better antiemetic control. This would allow clinicians to [18, [26] [27] [28] , the most important being the emetogenic potential of chemotherapy received [21] [22] [23] 29] . Other factors include female gender [18, 27, 28] , younger age [20, 24, 27, 28] , a history of NV (e.g. motion sickness, previous chemotherapy-induced NV) [24, 28] or low alcohol consumption [24, 27] , pre-existing anxiety [24, 28] , a high expectation of developing NV after chemotherapy [27, 28] , emetogenic potential of radiotherapy [7, [21] [22] [23] , and undergoing combined therapy [21, 23] .
Findings from previous studies examining TINV have been compromised by many shortcomings. The great majority have assessed NV in relation to single modality treatment, usually chemotherapy, as opposed to the combined treatments (e.g. chemoradiation) that patients have increasingly received in recent years. Additionally, those examining chemotherapy-induced NV often did so after a single cycle rather than multiple cycles [25] and focused on moderately/highly emetogenic chemotherapy [12] [13] [14] [15] [16] [17] to the exclusion of minimally/low emetogenic chemotherapy [25, 30] . Finally, few published studies have investigated TINV outside of randomised controlled trial (RCT) settings [14, 27] . Prospective clinical trial patients are often excluded if they have received prior chemotherapy [12, 18] or are scheduled for concurrent chemoradiation [7] . Moreover, trial patients typically have good performance status [14] , and many trials have compared novel antiemetics to non-standard treatment control arms [27] . Consequently, the results of antiemetic clinical trials lack generalisability to the wider population of cancer patients undergoing emetogenic cancer treatment.
The purpose of the present study was to address the major shortcomings of previous research. Specifically, the aim was to assess the "real world" incidence of TINV (i.e. acute + delayed NV) in cancer patients receiving combined treatment in a routine clinical setting. Potential risk factors predicting the development of TIN and TIV, respectively, were also evaluated.
Materials and methods
A prospective, longitudinal, observational design involving a heterogeneous group of 200 cancer patients was employed. The ethics committees of the participating institutions approved the study. All patients provided written and informed consent.
Patients
Participants were recruited from a consecutive series of 287 eligible medical oncology outpatients who largely received combined treatment (including chemotherapy) at Royal Perth Hospital, Western Australia between 1997 and 2003. They were recruited for a larger study evaluating QOL and psychosocial distress. Patients were approached in the week prior to the commencement of their cancer treatment and given an explanation of the study plus an information sheet to help them decide on participation.
Eligibility criteria
Eligibility criteria included histological confirmation of cancer, age 18 years and over, absence of acute psychiatric symptoms or conditions that could cause emesis (e.g. central nervous system metastasis, gastrointestinal obstruction), no prior cancer treatment for the current diagnosis (excluding surgery) and adequate English literacy to complete study questionnaires.
Data collection
Data concerning demographics, clinical characteristics and potential risk factors for TINV were collected from patients, oncologists and medical records. Questionnaires were completed by patients four times: at pretreatment (within 7 days of the start of chemotherapy ± radiotherapy), on-treatment (8 weeks±1 week), post-treatment (within 7 days of the last treatment received) and follow-up (6 months). Follow-up data is beyond the scope of the present study and will not be reported here. Data was excluded for patients if questionnaires were not completed within the specified timeframes.
On-/post-treatment assessments occurred at 7 days following the end of treatment cycles to capture both acute and delayed NV (i.e. TINV incidence), as well as other treatment effects. The on-treatment assessment was also performed at 8 weeks (±1 week), chiefly, to minimise patient burden associated with more frequent or ongoing assessment (e.g. patient diaries) that would have added to the more extensive battery of questionnaires (100 items) employed in the larger QOL study. Furthermore, it was considered an optimal time point to measure the incidence of acute and delayed NV (and other side effects) during treatment, as it coincided with the administration of chemotherapy (undertaken by all patients, unlike radiotherapy and surgery) that was generally given weekly or every 3-4 weeks for a period of 3-12 months.
Questionnaires
Patients were administered standardised questionnaires assessing QOL and psychosocial distress: [34] is an abridged 13-item scale measuring the cognitive-affective aspects of clinical depression, while excluding somatic symptoms manifested in medical populations. Patients were asked to rate items describing how they had felt during the previous week. 4. The Impact of Event Scale-Intrusion Subscale (IES-IS) [35] is a seven-item scale measuring cognitive-emotional distress related to a major stressor. Patients were asked to rate the frequency of intrusive thoughts relating to cancer that occurred in the preceding week. 5. The Eysenck Personality Questionnaire-revised (EPQ-R) Neuroticism short form (SF) [36] is an abbreviated 12-item scale that was used to measure premorbid levels of neuroticism at pretreatment only.
Statistical analysis
Internal consistency of the multi-item scales was calculated using Cronbach's alpha. Dependence or association of patient, clinical and pretreatment QOL/psychological factors with TINV incidence (the presence of at least one episode of nausea, vomiting or retching during treatment, irrespective of intensity, as assessed via the EORTC QLQ-C30) were examined via Pearson Chi-square analyses in patients with and without TINV. Mean differences between patients with and without TINV in pretreatment QOL and psychological function were examined via univariate analyses using oneway analyses of covariance. Multivariate logistic regression was performed to identify independent risk factors predicting the development of TIN and TIV separately. The level of significance was set at p≤0.1 for retention of predictor variables in both risk factor models. The level of significance for all analyses, however, was set at p≤0.05.
Results

Patient characteristics
Two hundred (70%) of the eligible patients consented and completed baseline questionnaires. Of these, 178 (89%) patients achieved on-treatment (8 weeks±1 week) and 153 (76%) progressed to post-treatment. During treatment, 47 patients were withdrawn due to death (15) , study ineligibility triggered by changes in medical care (15), study withdrawal (15) and loss to follow-up (two). Patient and clinical characteristics are shown in Table 2 . The cohort included 48% males and 52% females, with mean age 56.3 years (SD=13.2; range, 24-85). Primary cancer diagnoses comprised 29% breast, 28% colorectal and 43% other, with 128 (64%) patients possessing localised or locally advanced disease. In terms of sex, age and diagnosis, the sample was quite representative of cancer patients in Western Australia at the time of the study [37] .
Of the 200 patients, 124 (66%) were treated for more than 3 months (median=151 days, excluding surgery prior to adjuvant chemotherapy ± radiotherapy) and 119 (60%) received adjuvant/neoadjuvant treatment. Additionally, 106 (53%) patients underwent surgery prior to adjuvant chemotherapy ± radiotherapy (cf. 67% in total) and 88 (44%) received radiotherapy as part of a combined treatment (23% concurrently with chemotherapy). All patients received chemotherapy; 161 (80%) were chemotherapy-naïve. Overall, 239 chemotherapy regimens were administered (range of cycles, 2-12; data incomplete); 5-fluorouracil + leucovorin (5-FU/LV, 19%) and cyclophosphamide + methotrexate + 5-FU (CMF, 11%) were most prevalent. The emetogenic potential of the chemotherapy (and radiotherapy) regimens the patients received was classified using the Multinational Association of Supportive Care in Cancer (MASCC) antiemetic guidelines [21] . One hundred and two (51%) patients received moderately/highly emetogenic chemotherapy (M/HEC; ≥30% emetic risk without prophylaxis; e.g. cisplatin-based regimens), and the remaining 98 (49%) received minimally/low emetogenic chemotherapy (M/LEC; <30% emetic risk without prophylaxis; e.g. gemcitabine). Antiemetic therapy consistent with guidelines available at the time of the study was used for the majority of patients [29, 38] . One hundred and thirty (65%) patients received 5-HT 3 receptor antagonists (e.g. ondansetron) + corticosteroids (e.g. dexamethasone) and 55 (28%) were prescribed dopamine receptor antagonists (e.g. metoclopramide) while 43 (22%) patients received no antiemetics. 
Risk factors of TIN and TIV
Risk factor models explaining TIN and TIV were derived by combining patient, clinical and pretreatment QOL/ psychological factors examined in univariate analyses above using multivariate logistic regression. Regression employed forced entry of previously established predictors (e.g. chemotherapy emetogenicity, sex) plus backward elimination of exploratory predictors (e.g. private health insurance) and retained variables with p≤0.1 (Table 6 ).
Patients were dichotomised as high or low scorers (above/ equal vs. below the mean) for all QOL and psychological risk factors except premorbid/anticipatory NV (present vs. absent). Overall, sex, premorbid/anticipatory NV, chemotherapy emetogenicity and cancer surgery were significantly associated with both TIN and TIV while age predicted neither. Seventy-three percent of TIN incidence among patients was predicted by eight independent risk factors. High premorbid/anticipatory NV (β=1.51), M/HEC (β=1.26), longer treatment (>3 months, excluding surgery prior to adjuvant chemotherapy ± radiotherapy; β=1.03), private health insurance (β=1.01) and sex (β=1.0) were most prominent. Notably, TIN incidence increased three to fivefold if patients experienced high premorbid/anticipatory NV (4.52) or received M/HEC (3.42). Additionally, incidence more than doubled if patients endured longer treatment (>3 months, excluding surgery prior to adjuvant chemotherapy ± radiotherapy; 2.8), had private health insurance (2.74), were female (2.72) or underwent surgery prior to adjuvant chemotherapy ± radiotherapy (2.37).
Similarly, 77% of TIV incidence was predicted by six independent risk factors. Premorbid/anticipatory vomiting 
Discussion
To our knowledge, the present observational study is the first to examine NV in cancer patients receiving chemotherapy, radiotherapy and/or surgery. Consequently, the 62% TINV rate reported in this study may be a more accurate gauge of "real world" incidence for cancer patients treated in everyday clinical settings than previous studies. Compared to the average incidence observed in previous cross-sectional studies (predominantly RCTs), patients predictably experienced a much higher rate (Table 1 ; 62% vs. 39%).
Comparisons to prior longitudinal studies (mostly prospective studies in routine settings) revealed similar disparity (Table 1 ; 62% vs. 45%) and is likely the result of patients in this study receiving longer, more extensive treatment. When TINV was dissected, however, development of TIN (60%) proved to be a more pervasive problem than TIV (27%). This contrast is sharpened by the fact that TIN alone was experienced by 35% of patients while only 2% reported TIV alone. Furthermore, TIN occurred in at least half of patients receiving M/LEC (50%) or M/HEC (70%) and was equally prominent in patients who underwent M/ LE (65%) or M/HE (50%) radiotherapy. Similar trends have been highlighted in previous research also [7, [25] [26] [27] .
While TIV was largely well controlled by clinicians overall, management of TIN was poor. Analysis of individual chemotherapy drugs revealed that none produced significant problems for TIV, but that a number were associated with poor TIN outcomes. Cyclophosphamide (known for its delayed emetogenicity) [40] produced the poorest outcomes, thus strengthening recently revised antiemetic guidelines [21] [22] [23] recommending that patients receiving an anthracycline + cyclophosphamide be given greater prophylaxis for both acute and delayed symptoms. Patients who did not receive antiemetics also reported TIN twice as often as TIV (40% vs. 19%). Antiemetics, however, appeared to have little impact on nausea with 65% of patients prescribed them experiencing TIN (cf. 29% TIV).
Nausea remains difficult to manage in clinical practice. Antiemetics in this study failed to provide adequate coverage and those currently in use, including the NK-1 antagonists, have drawn no closer toward complete prevention of nausea. As previously reported [4, 25] , antiemetic control has primarily focused on vomiting to the detriment of nausea. Whilst this offers a straightforward explanation for poor TIN outcomes, it ignores the more pragmatic reasons underlying this state of affairs. Our understanding of nausea, for one, is far from complete. As in other studies [7, 27] , TIN was frequently observed among patients without TIV, suggesting the involvement of different neural pathways in its aetiology and the need for nausea and vomiting to be treated as separate entities requiring different drugs. Further, studies (the present one included) have suggested that anticipatory (conditioned) nausea may contribute to subsequent experiences of TIN over repeated [41, 42] . Many other reasons may explain poor TIN outcomes, including the subjective nature of nausea, inadequate assessment, underreporting among patients, and clinicians' underestimation of TIN incidence and its effect on patients' lives [25, 26] . Indeed, patients rate nausea as more distressing than vomiting [3, 43] and it significantly impacts on their QOL [43] . Consequently, clinicians cannot effectively manage TIN unless they demonstrate a greater appreciation of the problem and make it as important a priority as TIV. M/LEC has received scant interest in antiemetic research. Among patients receiving M/LEC in the present study, 50% experienced TIN and 20% reported TIV. While individual M/LEC drugs posed no significant problems for TIV, 5-FU was associated with poor TIN outcomes; this is consistent with at least one other study [25] . Current antiemetic guidelines [21] [22] [23] recommend no prophylaxis for patients receiving M/LEC, with the exception of acute nausea in those receiving LEC such as 5-FU. Furthermore, no consideration is given to the additive effect of individual M/LEC agents combined with other drugs (e.g. irinotecan, ifosfamide). Prospective trials assessing TINV incidence/ severity in patients receiving M/LEC agents (individually or in combination with other drugs) are needed to better assist clinicians with antiemetic control. Failing that, clinicians need to assess this patient subgroup and identify early those at high risk of TINV who would benefit from antiemetics.
Risk factor models can be powerfully utilised by clinicians to optimise antiemetic control for their patients. While a handful of models exist [7, 18, 27, 28] , none relate to combined treatment and most precede the introduction of the 5-HT 3 antagonists and treat TIN and TIV as a single entity. Consequently, they may lack relevant factors important to predicting TIN or TIV among patients in modern day settings. The present study identified several pretreatment factors that may help clinicians to identify patients at high risk of developing TIN or TIV. Independent predictors of TIN included high premorbid/anticipatory NV, M/HEC, longer treatment (>3 months, excluding surgery prior to adjuvant chemotherapy ± radiotherapy), female gender, surgery prior to adjuvant chemotherapy ± radiotherapy, private health insurance and low emotional functioning. Notably, TIN incidence increased three to fivefold if the patients had high premorbid/anticipatory NV or received M/HEC, and at least doubled if they possessed any of the remaining risk factors. Predictors of TIV included premorbid/anticipatory vomiting, M/HEC, female gender, cancer resection and low role functioning. Remarkably, TIV incidence increased more than tenfold if the patients experienced premorbid/anticipatory vomiting, and at least doubled if they held any of the remaining risk factors (except cancer resection). These results partially confirm the findings of an earlier study by Osoba and colleagues [18] , which assessed similar predictors (albeit in relation to postchemotherapy NV). Additionally, the results lend support to the importance of non-pharmacological risk factors over and above that of chemotherapy emetogenicity, which has been demonstrated in previous studies [18, 24, 27, 28, 41, 42] . Overall, outcomes of the risk factor analyses provided further evidence that TIN is a more complex phenomenon than TIV and that clinicians face a tougher task managing it. Eight risk independent factors predicted 73% of TIN incidence while only six factors explained 77% of TIV incidence (Table 6) . Surprisingly, younger age was not identified as a significant risk factor in the development of either TIN or TIV, although other studies have also failed to do so [7, 18] , and such patient factors can be inconsistent in their effects on TINV [44] . Also interesting was that patients with private health insurance were at increased risk to TIN. This may be explained by the fact that 50% or more of chemotherapy is administered to private health patients in Australia [45] ; anecdotal evidence suggests that they potentially have greater psychosocial issues than public health patients [46] , which may be associated with elevated risk to TIN. Further research is advised, however, given the relatively small number of private health patients in this study. Finally, outside chemotherapy, cancer surgery was identified as a more important risk factor than radiotherapy for the development of both TIN and TIV in the course of combined treatment. Again, this may have been due to the relatively low number of patients who received M/HE radiotherapy. Multicentre studies involving larger samples are needed to further investigate these observations. Several patient, clinical and QOL/psychological factors were significantly associated with TIN while psychological factors contributed little to TIV. Pre-existing anxiety and nausea are risk factors for NV that increase in importance over successive cycles of chemotherapy [24, 28, 41] . In the present study, low emotional functioning (high anxiety/ worry) and premorbid/anticipatory nausea and vomiting were identified as independent risk factors for TIN together with longer treatment. Collectively, this suggests that patients' psychological functioning may play a more important role in the development of delayed TIN than acute TIN. Given the poor control of TIN exerted by antiemetics alone, clinicians should consider employing additional interventions (including combined pharmacological and non-pharmacological approaches) in attempts to improve management for their patients. Supplementing antiemetics with interventions dealing with pre-existing anxiety (e.g. anxiolytics [47] , acupuncture/acupressure [48] , relaxation techniques [49] ) has been shown to reduce chemotherapy-induced NV in RCTs and should be offered to patients exhibiting such risk factors for TINV incidence when screened at pretreatment. While some nonpharmacological approaches such as acupuncture are time and labour intensive (and others like relaxation techniques are not), it should not preclude their regular use in antiemetic control by clinicians if significantly better outcomes can be achieved for patients (particularly in instances, such as TIN, where antiemetics alone have demonstrated limited efficacy). Finally, and in addition to supplementing antiemetics with other interventions, controlled antiemetic trials should seek to incorporate pretreatment risk factors in their evaluation of TINV development.
Some limitations of the present study must be acknowledged. Antiemetic guidelines [21] [22] [23] for patients receiving HEC have been amended since this study was performed to include use of the newer NK-1 antagonists. Consequently, results of the present study may not generalise to current cancer patients. This may only apply to TIV, however, as the NK-1 antagonists have not demonstrated greater control over chemotherapy-induced nausea compared to standard antiemetic therapy [50] . Heterogeneity of the sample in terms of diagnosis, disease stage, treatment received and antiemetics used could also limit the generalisability of results. Nevertheless, the authors believe that the results better reflect the "real world" incidence of TINV and its risk factors in routine clinical practice than most studies to date. Another limitation is that the EORTC QLQ-C30s assessment of TINV is rudimentary compared to more comprehensive measures such as patient diaries and the MASCC Antiemesis Tool [52] (e.g. frequency of vomiting episodes is not recorded, the extent of nausea is subjectively quantified on a Likert rating scale), thus underestimating the incidence and experience of TIN and TIV in this study. Additionally, information on the number of chemotherapy cycles and radiotherapy fractions would have provided greater insight into TINV outcomes in the present study (particularly given the heterogenous sample), but unfortunately could not be utilised due to unacceptable amounts of missing/unavailable data. Finally, the pretreatment factors assessed in this study only partially explained the variance in TIN and TIV development. Predictors not considered (e.g. patients' pretreatment expectations of developing TINV) must therefore account for the unexplained variance. Larger multicentre studies involving a wider range of possible risk factors, more comprehensive measures of TINV and use of current antiemetic guidelines are needed to address these limitations.
Conclusion
Several patient, clinical and pretreatment QOL/psychological variables in this study were identified as independent risk factors for TIN and TIV, respectively. Patients about to undergo cancer treatment, particularly combined treatment involving emetogenic chemotherapy and surgery, should be screened for these factors with a view to modifying standard pretreatment/maintenance antiemetic therapy. Furthermore, additional interventions combining antiemetics with other effective pharmacological (e.g. anxiolytics) and non-pharmacological approaches (e.g. acupuncture, relaxation techniques) should be considered by clinicians in attempts to improve control of TIN and TIV (and concomitant QOL), particularly for patients at high risk. However, optimal control will not be achieved with these strategies unless greater recognition of these symptoms is shown by clinicians and patients alike. Patients must be educated about TINV [7] , particularly with respect to nausea per se and delayed symptoms that take place outside treatment settings. Finally, they must be regularly assessed and improved communication must be facilitated between clinicians/nurses and patients regarding the symptom experience and any self-help strategies undertaken [25] .
